- Home
- SCNX vs BOLD Comparison
SCNX vs BOLD Comparison
Compare SCNX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- BOLD
- Stock Information
- Founded
- SCNX 2010
- BOLD 2018
- Country
- SCNX United States
- BOLD United States
- Employees
- SCNX N/A
- BOLD N/A
- Industry
- SCNX Other Pharmaceuticals
- BOLD
- Sector
- SCNX Health Care
- BOLD
- Exchange
- SCNX Nasdaq
- BOLD Nasdaq
- Market Cap
- SCNX 31.5M
- BOLD 33.4M
- IPO Year
- SCNX 2020
- BOLD 2024
- Fundamental
- Price
- SCNX $0.82
- BOLD $1.30
- Analyst Decision
- SCNX
- BOLD Buy
- Analyst Count
- SCNX 0
- BOLD 4
- Target Price
- SCNX N/A
- BOLD $4.00
- AVG Volume (30 Days)
- SCNX 63.1M
- BOLD 167.9K
- Earning Date
- SCNX 11-12-2025
- BOLD 11-05-2025
- Dividend Yield
- SCNX N/A
- BOLD N/A
- EPS Growth
- SCNX N/A
- BOLD N/A
- EPS
- SCNX N/A
- BOLD N/A
- Revenue
- SCNX $128,202.00
- BOLD N/A
- Revenue This Year
- SCNX N/A
- BOLD N/A
- Revenue Next Year
- SCNX N/A
- BOLD N/A
- P/E Ratio
- SCNX N/A
- BOLD N/A
- Revenue Growth
- SCNX N/A
- BOLD N/A
- 52 Week Low
- SCNX $0.46
- BOLD $1.00
- 52 Week High
- SCNX $8.81
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- SCNX 48.09
- BOLD 45.40
- Support Level
- SCNX $0.69
- BOLD $1.37
- Resistance Level
- SCNX $1.10
- BOLD $1.52
- Average True Range (ATR)
- SCNX 0.34
- BOLD 0.08
- MACD
- SCNX -0.02
- BOLD -0.02
- Stochastic Oscillator
- SCNX 16.70
- BOLD 7.37
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.